Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 13 Jan 2020
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 6 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).

Intraocular lens implantation not recommended for infants

11 Oct 2019
Abbott opens us$60 million plant in Kedah

Implantation of intraocular lens (IOL) during early childhood leads to a higher incidence of visual axis opacities compared with aphakia, making it not suitable for children aged 6 months, reports a study.

“The best available evidence suggests that IOL implantation can be done safely with acceptable side effects in children older than 6 months of age,” the investigators said.

“However, the unpredictability of ocular growth means that these children will often have large refractive errors later in childhood that may necessitate an IOL exchange or wearing spectacles or contact lenses with a large refractive correction,” they added.

IOLs correlated with an increased risk of visual axis opacities and with visual outcomes similar to those for contact lenses or spectacles for children who had both bilateral and unilateral cataracts. All treatments resulted in a comparable incidence of glaucoma.

All treatments had similar ocular growth, but infants aged <6 months who underwent IOL implantation had large myopic shifts that often led to high myopia or severe anisometropia later in childhood. In addition, eyes that underwent IOL implantation had lower corneal endothelial cell counts.

All treatments were associated with a similar incidence of strabismus.

“[T]he training and experience of the surgeon, as well as ocular and systemic comorbidities, should be taken into consideration when deciding whether IOL implantation would be appropriate,” the investigators said.

This study accessed PubMed, the Cochrane Library and the databases of clinical trials in February 2019 without date or language restrictions, resulting in 194 potentially relevant citations. Of these, 34 were selected for full-text review. Fourteen studies met the eligibility criteria and were included in the analysis. A level of evidence rating was then assigned to these studies by the panel methodologist.

Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 13 Jan 2020
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 6 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).